Cargando…

Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer

SIMPLE SUMMARY: Expression of MERTK and/or AXL (members of the TAM family of receptor tyrosine kinases) provides a survival advantage for non-small cell lung cancer (NSCLC) cells and correlates with lymph node metastasis, drug resistance, and disease progression. TAM receptors on host tumor infiltra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Dan, Earp, H. Shelton, DeRyckere, Deborah, Graham, Douglas K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616094/ https://www.ncbi.nlm.nih.gov/pubmed/34830794 http://dx.doi.org/10.3390/cancers13225639

Ejemplares similares

MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
por: Yan, Dan, et al.
Publicado: (2022)

Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia
por: Summers, Ryan J., et al.
Publicado: (2022)

MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme
por: Sufit, Alexandra, et al.
Publicado: (2016)

MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity
por: Lee-Sherick, Alisa B., et al.
Publicado: (2020)

Targeting the TAM Receptors in Leukemia
por: Huey, Madeline G., et al.
Publicado: (2016)

Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer
por: Cummings, Christopher T., et al.
Publicado: (2014)

The role of endothelial MERTK during the inflammatory response in lungs
por: Li, Yitong, et al.
Publicado: (2019)

Mer or Axl Receptor Tyrosine Kinase Inhibition Promotes Apoptosis, Blocks Growth, and Enhances Chemosensitivity of Human Non-Small Cell Lung Cancer
por: Linger, Rachel M.A., et al.
Publicado: (2012)

Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia
por: Brandao, L N, et al.
Publicado: (2013)

Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment
por: Myers, Kayla V., et al.
Publicado: (2019)

A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity
por: Rios-Doria, Jonathan, et al.
Publicado: (2020)

Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation
por: Zhou, Junsong, et al.
Publicado: (2018)

The Emerging Role of TYRO3 as a Therapeutic Target in Cancer
por: Smart, Sherri K., et al.
Publicado: (2018)

The Current State of FLT3 Inhibition in Acute Myeloid Leukemia – Pitfalls and Promises
por: Minson, Katherine A, et al.
Publicado: (2017)

Dual targeting of TAM receptors Tyro3, Axl, and MerTK: Role in tumors and the tumor immune microenvironment
por: Wang, Kai-Hung, et al.
Publicado: (2020)

Receptor tyrosine kinases Tyro3, Axl, and Mertk differentially contribute to antibody-induced arthritis
por: Gao, Liang, et al.
Publicado: (2023)

MerTK is required for apoptotic cell–induced T cell tolerance
por: Wallet, Mark A., et al.
Publicado: (2008)

MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
por: Chen, Chao-Ju, et al.
Publicado: (2021)

Correction: Receptor tyrosine kinases Tyro3, Axl, and Mertk differentially contribute to antibody-induced arthritis
por: Gao, Liang, et al.
Publicado: (2023)

Axl and MerTK receptor tyrosine kinases maintain human macrophage efferocytic capacity in the presence of viral triggers
por: Grabiec, Aleksander M, et al.
Publicado: (2018)

Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer
por: Zhang, Zhenfeng, et al.
Publicado: (2012)

Intervention of AXL in EGFR Signaling via Phosphorylation and Stabilization of MIG6 in Non-Small Cell Lung Cancer
por: Yang, Ya-Yu, et al.
Publicado: (2023)

Tyrosine Kinase Receptors Axl and MerTK Mediate the Beneficial Effect of Electroacupuncture in a Cuprizone-Induced Demyelinating Model
por: Zou, Zaofeng, et al.
Publicado: (2020)

Harnessing MerTK agonism for targeted therapeutics
por: Kedage, Vivekananda, et al.
Publicado: (2019)

Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia
por: Lee-Sherick, Alisa B., et al.
Publicado: (2015)

Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer
por: Wang, Feng, et al.
Publicado: (2019)

Tyro3/Axl/Mertk-deficient mice develop bone marrow edema which is an early pathological marker in rheumatoid arthritis
por: Waterborg, Claire E. J., et al.
Publicado: (2018)

AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
por: Noronha, Ashish, et al.
Publicado: (2022)

Role of AXL expression in non-small cell lung cancer
por: Qu, Xiaohan, et al.
Publicado: (2016)

MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression
por: Jiang, Yao, et al.
Publicado: (2019)

AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
por: Kim, Donghwa, et al.
Publicado: (2019)

Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
por: Zhang, Shi-Ling, et al.
Publicado: (2023)

High levels of AXL expression in untreated EGFR ‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib
por: Yoshimura, Akihiro, et al.
Publicado: (2022)

Requirement of Gamma-Carboxyglutamic Acid Modification and Phosphatidylserine Binding for the Activation of Tyro3, Axl, and Mertk Receptors by Growth Arrest-Specific 6
por: Geng, Ke, et al.
Publicado: (2017)

The miR-625-3p/AXL axis induces non-T790M acquired resistance to EGFR-TKI via activation of the TGF-β/Smad pathway and EMT in EGFR-mutant non-small cell lung cancer
por: Du, Wenwen, et al.
Publicado: (2020)

Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Axl-Targeted Delivery of the Oncosuppressor miR-137 in Non-small-Cell Lung Cancer
por: Nuzzo, Silvia, et al.
Publicado: (2019)

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis
por: Karachaliou, Niki, et al.
Publicado: (2018)

Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells
por: Tian, Yaqiong, et al.
Publicado: (2016)

Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway
por: Sun, Qi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_of9apkqvuspj203q9jj16j2em8